GKOS - GLAUKOS CORPRTN （）

https://www.investing.com/news/pro/glaukos-corporation-pt-lowered-to-68-at-stephens-432SI-2970698

In Friday’s session, Glaukos Corporation (NYSE:GKOS) marked $42.63 per share, down from $43.08 in the previous session. While Glaukos Corporation has underperformed by -1.04%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GKOS fell by -8.91%, with highs and lows ranging from $64.49 to $33.33, whereas […]

https://www.investing.com/news/pro/mizuho-securities-starts-glaukos-corporation-at-neutral-432SI-2969123

This report was sent to Briefing.com subscribers earlier today. Upgrades: > American Equity Investment Life (AEL) upgraded to Strong Buy from Outperform at Raymond James; tgt $48 > Enphase Energy (ENPH) upgraded to Outperform from Market Perform at Northland Capital; tgt $365 > Glaukos (GKOS) upgraded to Neutral from Underweight at JP Morgan; tgt lowered […]

Glaukos Corporation (NYSE:GKOS) concluded the trading at $42.48 on Friday, December 16 with a fall of -1.94% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $43.32 and 5Y monthly beta was reading 1.29 with its price kept floating in the range … Analysts Offer Important Insight On Glaukos Corporation (GKOS) Read More »

Glaukos shares fall post Q3 earnings announcement despite top-line guidance hike. Click here to read my analysis of GKOS stock.

Glaukos Corp Earnings Miss, Revenue Beats In Q3

Glaukos Corporation (NYSE:NYSE:GKOS) Q3 2022 Earnings Conference Call November 02, 2022 04:30 PM ET Company Participants Chris Lewis - Vice President-Investor Relations & Corporate…

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2022. Key highlights include: Net sales of $71.3 million in Q3 2022. Glaucoma net sales of $53.7 million and Corneal Health net sales of $17.5 million in Q3 2022. Gross margin of approximately

https://www.investing.com/news/pro/stephens-resumes-glaukos-corporation-at-overweight-432SI-2911944

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held September 30 - October 3, 2022 in Chicago,

Gainers IMARA Inc. (NASDAQ: IMRA ) jumped 74.8% to settle at $2.01 on Wednesday after the company announced it entered into an asset purchase agreement with Cardurion Pharmaceuticals to sell tovinontrine and other assets of its PDE9 program for $34.75 million upfront. Azure Power Global Limited (NYSE: AZRE ) shares jumped 35.4% to close at $4.86. Azure Power Global recently announced the resignation of Harsh Shah as CEO. SelectQuote, Inc. (NYSE: SLQT ) rose 28.8% to close at $1.43. Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH ) gained 27.7% to close at $36.40 amid post-IPO volatility. Spero Therapeutics, Inc. (NASDAQ: SPRO ) shares jumped 26.6% to close at $1.43. Spero Therapeutics shares jumped over 55% on Tuesday after the company received minutes from a Type A meeting with the FDA discussing steps required to resubmit the marketing application for tebipenem HBr. a.k.a. Brands Holding Corp. (NYSE: AKA ) gained 23.7% to settle at $2.92 amid overall market strength as stocks rebound from recent weakness.

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Wednesday: EQT Corp., up 57 cents to $46. The natural gas company announced the purchase of gas and pipeline assets and doubled its stock buyback program. Coupa Software Inc., up $10 to $65.82. The software company reported strong second-quarter financial results. HealthEquity Inc., up 64 cents to $64.08. The provider of services for managing health care accounts raised its revenue forecast for the year. Occidental Petroleum Corp., down $1.45 to $65.43. Energy stocks slipped along with falling oil prices. Target Corp., up $7.21 to $170.79. The retailer is dropping the mandatory retirement age for its CEO, allowing Brian Cornell to stay on for three more years. United Parcel Service Inc., up 33 cents to $196.29. The package delivery service plans to hire more than 100,000 extra workers to help handle an increase in packages during the critical holiday season. Glaukos Corp., up $8.91 to $57.01. The drug developer gave investors an encouraging update on a potential glaucoma treatment.

U.S. stocks traded higher toward the end of trading, with the Dow Jones adding around 450 points on Wednesday. The Dow traded up 1.45% to 31,596.87 while the NASDAQ rose 1.99% to 11,774.77. The S&P 500 also rose, gaining, 1.74% to 3,976.30. Also check this: Fear & Greed Index Remains In ''Fear'' Zone As US Stocks Drop Leading and Lagging Sectors Utilities shares jumped by 2.6% on Tuesday. Meanwhile, top gainers in the sector included Azure Power Global Limited (NYSE: AZRE ), up 32% and Sunnova Energy International Inc. (NYSE: NOVA ) up 10%. In trading on Tuesday, energy shares fell by 1.5%. Top Headline The trade deficit narrowed by $10.2 billion to a nine-month low level of $70.7 billion in July. Exports from the US rose by 0.2% from the prior month to $259.3 billion, while imports fell 2.9% to $329.9 billion. Equities Trading UP Glaukos Corporation (NYSE: GKOS ) shares shot up 25% to $60.29 after the company announced topline data for both Phase 3 pivotal trials of iDose TR that successfully achieved its pre-specified primary efficacy endpoints through 3 months in both Phase 3 trials and demonstrated excellent tolerability and a favorable safety …